Clinical Trials Logo

Acne Vulgaris clinical trials

View clinical trials related to Acne Vulgaris.

Filter by:

NCT ID: NCT01628549 Completed - Acne Vulgaris Clinical Trials

Double-Blind, Placebo-Controlled Study to Evaluate 3 Doses of a Novel Tetracycline in the Treatment of Facial Acne Vulgaris

Start date: June 30, 2012
Phase: Phase 2
Study type: Interventional

To evaluate the safety and effectiveness of 3 strengths of P005672-HCl compared to placebo for the treatment of moderate to severe facial acne vulgaris.

NCT ID: NCT01618773 Completed - Acne Vulgaris Clinical Trials

Long-term Study of Epiduo in Patients With Moderate to Severe Acne

ELANG
Start date: June 2012
Phase: N/A
Study type: Observational

This observational study is designed to assess the long-term efficacy and safety of Epiduo (alone or in combination with other drugs) under daily clinical practice conditions in patients with moderate to severe inflammatory acne. In addition, the effect of Epiduo on quality of life and patient adherence will be assessed under marketed conditions.

NCT ID: NCT01616654 Completed - Acne Vulgaris Clinical Trials

Dose Range Study of CD5789 in Acne Vulgaris

Start date: June 20, 2012
Phase: Phase 2
Study type: Interventional

To assess the efficacy and safety of different concentrations of CD5789 cream in participants with acne vulgaris for the purpose of dose identification.

NCT ID: NCT01584674 Completed - Acne Vulgaris Clinical Trials

A Clinical Trial Evaluating the Safety and Efficacy of the KLOX Biophotonic System in Moderate to Severe Acne

Start date: March 2012
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of the KLOX Biophotonic System in patients with moderate to severe facial acne vulgaris using a split-face design (treated hemiface vs untreated hemiface).

NCT ID: NCT01556698 Completed - Acne Vulgaris Clinical Trials

Study of NVN1000 Topical Gel and Topical Gel Vehicle in the Treatment of Moderate to Severe Acne Vulgaris

Start date: July 2011
Phase: Phase 1/Phase 2
Study type: Interventional

The primary objective of this study is to compare the tolerability, safety and efficacy of NVN1000 Topical Gel and Topical Gel Vehicle in the treatment of subjects with moderate to severe acne vulgaris.

NCT ID: NCT01527123 Completed - Acne Vulgaris Clinical Trials

A Study to Evaluate the Pharmacokinetics of Benzoic Acid and Hippuric Acid After Topical Administration of GSK2585823 in Japanese Subjects With Acne Vulgaris

Start date: February 28, 2012
Phase: Phase 1
Study type: Interventional

This is a Phase 1, single-center, open-label study to evaluate the pharmacokinetics of the BPO metabolites benzoic acid and hippuric acid with 7-day repeat application of GSK2585823 in subjects with acne vulgaris

NCT ID: NCT01522456 Completed - Acne Vulgaris Clinical Trials

Split-face Tolerability Comparison Between Adapalene-Benzoyl Peroxide Gel Versus Tretinoin Gel

Start date: April 2012
Phase: Phase 4
Study type: Interventional

To compare the tolerability of Epiduo® (adapalene and benzoyl peroxide) Gel 0.1%/2.5% to Retin-A Micro® (tretinoin gel) microsphere when used by subjects with acne vulgaris for 3 weeks in terms of local tolerability parameters (erythema, dryness, scaling, stinging/burning) and preference.

NCT ID: NCT01504204 Completed - Acne Vulgaris Clinical Trials

Effect of Samples on Acne Treatment With Epiduo® Gel

Start date: December 2011
Phase: Phase 4
Study type: Interventional

The purpose of this study is to compare adherence to treatment and efficacy with Epiduo® Gel in patients with mild to moderate acne who receive a medication sample and instructions on proper application with their stock size medication tube versus patients who receive only the stock size medication tube.

NCT ID: NCT01501799 Completed - Acne Vulgaris Clinical Trials

A Bioequivalence Study With Clinical Endpoints Comparing Adapalene and Benzoyl Peroxide Topical Gel 0.1%/2.5% (Actavis Mid-Atlantic LLC) To Epiduo™ (Adapalene and Benzoyl Peroxide) Gel 0.1%/2.5% (Galderma Laboratories, L.P.) in the Treatment of Mild to Severe Acne Vulgaris

Start date: July 2011
Phase: N/A
Study type: Interventional

EPIDUO™ (adapalene and benzoyl peroxide) Gel 0.1%/2.5%, marketed by GALDERMA LABORATORIES, L.P., is a safe and effective topical therapy used for the treatment of acne vulgaris. Actavis Mid-Atlantic LLC has developed a generic formulation of adapalene and benzoyl peroxide topical gel 0.1%/2.5%,and the current study is designed to evaluate the safety and efficacy of this formulation to determine if it is bioequivalent to EPIDUO™.

NCT ID: NCT01498874 Completed - Acne Vulgaris Clinical Trials

Efficacy and Safety Study of Gevokizumab to Treat Moderate to Severe Acne Vulgaris

Start date: December 2011
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether gevokizumab is effective in the treatment of moderate to severe acne vulgaris.